

---

## Product Data Sheet

---

Product Name: PF-8380 hydrochloride

Cat. No.: GC36886

**Chemical Properties**

Cas. No. 2070015-01-7

SMILES O=C(N1CCN(CC1)CCC(C2=CC(O3)=C(C=C2)NC3=O)=O)OCC4=CC(Cl)=CC(Cl)=C4.[H]ClFormula  $C_{22}H_{22}Cl_3N_3O_5$ 

M.Wt 514.79

Solubility DMSO:  $\geq 5.2$  mg/mL (10.10 mM); Water:  $< 0.1$  mg/mL (insoluble)

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Autotaxin converts lysophosphatidylcholine to lysophosphatidic acid (LPA), which can mediate changes in cell proliferation, angiogenesis, and cytokine secretion.<sup>1</sup> PF-8380 is a potent inhibitor of autotaxin ( $IC_{50} = 2.8$  nM in an enzyme assay), the enzyme that converts lysophosphatidylcholine to lysophosphatidic acid (LPA).<sup>1</sup> It reverses MMP-13 expression induced by leptin in human OA chondrocytes when used at a concentration of  $10^{-6}$  M.<sup>2</sup> PF-8380 (30 mg/kg) reduces LPA production by  $>95\%$  following carrageenan-induced inflammation in rats and inhibits autotaxin activity in human whole blood ( $IC_{50} = 101$  nM).<sup>1</sup>

1. Gierse, J., Thorarensen, A., Beltey, K., et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. *J. Pharmacol. Exp. Ther.* 334(1):310-317 (2010)  
 2. Datta, P., Zhang, Y., Parousis, A., et al. High-fat diet-induced acceleration of osteoarthritis is associated with a distinct and sustained plasma metabolite signature. *Sci. Rep.* 7(1):8205 (2017)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---